Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.41 USD | -2.82% | +4.78% | -24.21% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.21% | 20.13M | |
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Transcript : Lumos Pharma, Inc. - Special Call